Analysts Conflicted on These Healthcare Names: Genmab (GMAB), CbdMD (YCBD) and SAGE Therapeutics (SAGE)
Optimistic Outlook: Buy Rating Affirmed for CbdMD Amid Growth Initiatives and Strategic Expansion
Maxim Group Initiates Coverage On CbdMD With Buy Rating, Announces Price Target of $3
CbdMD Analyst Ratings
No Data